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The prevalence of GH-secreting pituitary tumors in domestic cats (Felis catus) is 10-fold greater than in
humans. The predominant inhibitory receptors of GH-secreting pituitary tumors are somatostatin
receptors (SSTRs) and D2 dopamine receptor (DRD2). The expression of these receptors is associated
with the response to somatostatin analog and dopamine agonist treatment in human patients with
acromegaly. The aim of this study was to describe pathological features of pituitaries from domestic cats
with acromegaly, pituitary receptor expression, and investigate correlates with clinical data, including
pituitary volume, time since diagnosis of diabetes, insulin requirement, and serum IGF1 concentration.
Loss of reticulin structure was identified in 15 of 21 pituitaries, of which 10 of 15 exhibited acinar
hyperplasia. SSTR1, SSTR2, SSTR5, and DRD2mRNA were identified in the feline pituitary whereas
SSTR3 and SSTR4were not. Expression ofSSTR1,SSTR2, and SSTR5was greater in acromegalic cats
compared with controls. A negative correlation was identified between DRD2 mRNA expression and
pituitary volume. The loss of DRD2 expression should be investigated as a mechanism allowing the
development of larger pituitary tumors.
Copyright © 2019 Endocrine Society
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Freeform/KeyWords: acromegaly, hypersomatotropism, somatostatin, dopamine receptor, cat
Acromegaly is typically caused by a functional GH-secreting pituitary adenoma in humans, and
this results in increased circulating IGF1 [1]. Medical management therapies for acromegaly
include GH receptor antagonists, dopamine receptor agonists, and somatostatin analogs, with
the latter being the medical therapy of choice in most cases [2, 3]. However, 30% to 65% of
patients with acromegaly receiving somatostatin analogs for 12 months fail to achieve bio-
chemical disease control [4–6]. This limited response to therapy is justification for ongoing
research to develop therapies that improve outcomes in medically managed patients [7].
Abbreviations: BSA, bovine serum albumin; CT, computed tomography; DAB, diaminobenzidine; HST, hypersomatotropism; IQR,
interquartile range; PBS, phosphate buffered saline; PRL, prolactin; RT, room temperature; RVC, Royal Veterinary College; SSTR,
somatostatin receptor.
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Animal models can provide insight into disease pathophysiology and are used for ther-
apeutic drug development. Transgenic rats, mice, and rabbits are commonly used as induced
acromegalic models by overexpression of GHRH or aryl hydrocarbon receptor–interacting
protein knockout [8–11]. However, these models do not replicate GH-secreting pituitary
adenomas identified in most human patients with acromegaly, and this might limit the
predictability of pharmacological studies of tumorous pituitary GH-secretion inhibition when
using them. Additionally, the study of a naturally occurring disease from an animal that lives
in a similar environment to humans would be favorable to account for the potential envi-
ronmental effects on pituitary dysfunction.
Spontaneous acromegaly/hypersomatotropism (HST) in domestic cats (Felis catus) is 10-
foldmore prevalent than in humans, affecting an estimated 1 in 800 cats [12–14]. Acromegaly
in cats parallels the disease in humans as far as being diagnosed in middle-aged to older
subjects and is associated with insulin resistance, acral growth, and cardiovascular com-
plications [12, 15]. Cats affected by acromegaly have achieved long-term clinical and bio-
chemical response to pasireotide and cabergoline but no other medical therapies [16–19]. The
somatostatin and dopamine receptor profile of feline GH-secreting adenomas is not known.
The receptor expression profile of these tumors might explain the poor response of feline
acromegalics to octreotide, which has high binding affinity for, and preferentially binds to,
somatostatin receptor (SSTR2), and L-deprenyl, amonoamine oxidaseB inhibitor that prolongs
the activity of dopamine, but a favorable response to pasireotide treatment [16, 20, 21].
The aim of the study was to investigate whether cats with naturally occurring acromegaly
are a suitable model for the human disease, as well as a species of interest from a veterinary
perspective. The study sought to describe the pituitary pathological findings, hormone,
somatostatin and dopamine receptor expression of cats with and without acromegaly. Ad-
ditionally, the receptor expression data were compared with clinical data.
1. Materials and Methods
The study was approved by the Royal Veterinary College (RVC) Ethics and Welfare Com-
mittee (URN 2014 1306).
A. Animals
Written informed consent was obtained from owners of all enrolled cats. Cats had a diagnosis of
acromegaly on the basis of appropriate clinical history, serum IGF1 concentration.1000 ng/mL
(reference interval, 200 to 700 ng/mL), which has a 95%positive predictive value for acromegaly
[12], and pituitary enlargement diagnosed using intracranial imaging (contrast enhanced CT)
or postmortem examination [12]. All acromegalic cats had concurrent diabetes mellitus that
was likely to be secondary to acromegaly, and they were receiving lente insulin (Caninsulin;
MSD Animal Health, Kenilworth, NJ), protamine zinc insulin (ProZinc; Boehringer Ingelheim,
Ingelheim am Rhein, Germany), or glargine insulin (Lantus; Sanofi, Paris, France) (HST
group). Nonacromegalic cats who did not have a clinical history consistent with acromegaly or
pituitary enlargement, but had undergone postmortem examination and whose owners con-
sented to be enrolled in the study, were consecutively recruited. All cats had previously been
patients of the QueenMother Hospital for Animals (RVC), Beaumont Animals’Hospital (RVC),
or People’s Dispensary for Sick Animals in London, United Kingdom. All cats had been
neutered, which is common in the United Kingdom for patient health and population control.
B. Cat Pituitary Tissue
Pituitary tissue was obtained at the time of postmortem examination or therapeutic hy-
pophysectomy. Tissue was fixed in RNAlaterTM (Sigma-Aldrich, Dorset, United Kingdom) or
snap frozen in liquid nitrogen and stored at 280°C until processed in batches. A section of
pituitary tissuewas also fixed in 10%w/v neutral buffered formalin, dehydrated in decreasing
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concentrations of ethanol, and then embedded into paraffin blocks and stored at room
temperature (RT). A summary of clinical characteristics of the enrolled cats is presented in
Table 1.
C. Reticulin Staining
Tissue sections were cut, deparaffinized and rehydrated as follows: 4-mm sections were cut
using a manual rotary microtome (Leica RM2235; Leica Biosystems, Newcastle upon Tyne,
United Kingdom) and air dried onto microscope slides (SuperfrostTM microscope slides;
Thermo Fisher Scientific, Loughborough, United Kingdom); deparaffinization of the sections
was performed by heating slides to 60°C for 5 minutes followed by two 5-minute immersions
in HistoClear (National Diagnostics, Atlanta, GA) or xylene (Sigma-Aldrich) and rehydration
of tissues in decreasing concentrations of ethanol. A commercially available reticulin staining
kit (reticulin stain ab150684; Abcam, Cambridge, United Kingdom) was used, and the
procedure was performed as per the manufacturer’s guidelines apart from use of 1 M am-
monium hydroxide, where the kit describes use of “concentrated ammonium hydroxide” to
make the “working ammoniacal silver solution.” A feline kidney tissue section was used as a
positive control for each batch of reticulin fiber staining.
Ten control pituitary samples were used to develop a reference interval for the number of
nuclei within each acinus and area of each acinus. Ten acini from each sample were randomly
selected from each pituitary. This resulted in 100 acini being used for reference interval
determination. This reference interval was then tested using two other control pituitary
samples. Three assessors (Dr. Christopher Scudder, Katarina Hazuchova, Veterinary In-
ternal Medicine Specialist, and Norelene Harrington, Specialist in Veterinary Pathology)
were used to determine whether pituitary acinar morphology was altered in pituitaries from
cats with acromegaly. Each assessor was asked the following questions: Is the acinar structure
altered? Are the acini increased in size? Is there loss of acinus structure? Is the distribution
focal, multifocal, or diffuse? Loss of acinus structure would be consistent with adenomatous
change, and an increased size of acini would be consistent with acinar hyperplasia. The upper
reference limit for acinar size is described in “Reticulin Staining” in the “Results,” and the
responses to the above questions were used to determine a consensus among assessors.
D. Immunohistochemistry
All pituitary samples used for immunohistochemistry had previously undergone hematoxylin
and eosin staining. Pituitary tissue embedded in paraffin blockswas cut into 4-mm sections
and air dried on positively charged slides (SuperfrostTM Plus microscope slides; Thermo
Fisher Scientific, Loughborough, United Kingdom). Immunohistochemistry was performed
as previously described [22] by deparaffinization and rehydration of the sections as per
reticulin staining. Antigen retrieval for GH immunostaining was not necessary. Antigen
retrieval for prolactin (PRL) and SSTR2 quantification was required. For PRL immuno-
staining, slides were immersed in a pH 9.0 Tris-EDTA buffer (10 mM Tris base, 1 mM EDTA
solution, 0.05%Tween® 20), followed bymicrowave heating at 650W for 4minutes four times.
For SSTR2 immunostaining, slides were immersed in 10 mM citrate buffer (pH 6) and
microwave heating at 650W for 4minutes four times. Slides were cooled to RT for 30minutes
followed by blocking of endogenous peroxidase by immersion in 3% v/v H2O2 for 10 minutes.
Nonspecific protein binding was blocked by immersion in a buffer containing PBS (Gibco,
Thermo Fisher Scientific, Loughborough, United Kingdom), 5% goat serum (Sigma-Aldrich),
1% BSA (Sigma-Aldrich), 0.1% w/v Triton™ X-100 (Sigma-Aldrich), and 0.05% Tween® 20
(Thermo Fisher Scientific, Loughborough, United Kingdom).
Primary antibody incubation was performed overnight in a cold room. Rabbit anti-porcine
GH and rabbit anti-porcine PRL antibodies were used [23, 24]. The primary antibodies were
delivered lyophilized and reconstituted using PBS to a concentration of 1 mg/mL for anti-
porcine GH antibody and 300 mg/mL for anti-porcine PRL antibody as per the manufacturer’s
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Table 1. Clinical Data of Cats in the Control and Acromegalic Groups
Age (y) Sex
Body
Weight
(kg) Breed Concurrent Disease Treatment
Insulin
(U/12 h)
Time
Diabetic
(m)
Pituitary
DV Height
(mm)
Pituitary
Volume
(cm3)
IGF1
(ng/mL)
Control group
1 11 M 3.7 Tonkinese DM Insulin: lente 2 5
2 12 M 5.0 ASH DM Insulin: PZI 1.5 16 173
3 14 M 4.7 DSH DM Insulin: PZI 2.5 12 468
4 10 M 4.4 DSH DM Insulin: lente 4.5 1
5 15 F 3.3 DSH DM Insulin: glargine 1 4 222
6 13 M 5.4 DSH Cardiomyopathy Furosemide,
pimobendan,
clopidogrel
7 13 F 3.1 DSH Lymphoma Prednisolone,
vincristine
8 15 F 3.4 DLH CKD
9 1 M 4.6 DSH CKD Aluminum
hydroxide
10 6 M 4.3 Oriental IMHA prednisolone
11 2 F 4.6 Savannah Cardiomyopathy None
12 9 M 6.5 Norwegian
Forest
Sepsis Multiple antibiotic
therapy
13 7 M DSH Pleural effusion
14 15 M 4.7 DSH CKD
15 16 M 6.6 DSH DM 4 868
16 8 M 4.0 DSH DM Newly diagnosed
17 2 F 3.5 DSH Myelodysplasia Prednisolone,
chlorambucil
18 16 F 3.1 DSH DM/
hyperaldosteronism
Insulin: glargine,
spironolactone
7
19 12 F 5.2 DSH CKD
20 1 F 4.1 DSH IMHA Prednisolone,
chlorambucil
21 15 M 4.3 DLH CKD Aluminum
hydroxide
22 18 M 3.9 DSH Gastrointestinal
disease: unclassified
HST group
1 11 F 6.6 DSH DM, chronic
enteropathy:
unclassified
Insulin: lente,
PAS-LAR
2 15 6.2 0.15 1598
2 11 M 5.7 DSH DM Insulin: glargine,
PAS-LAR
2 10 5.0 0.09 .2000
3 10 M 4.9 DSH DM, hepatopathy:
unclassified
Insulin: glargine 0.5 15 10.0 0.58 1271
4 13 M 4.2 DLH DM Insulin: lente 7 13 6.6 0.08 1824
5 14 M 4.1 DSH DM/HCM Insulin: lente,
PAS-LAR,
aspirin
3 53 6.4 0.05 1716
6 10 M 8.0 DSH DM Insulin: glargine 0.5 4 5.0 N/A 1629
7 13 M 6.5 DSH DM Insulin: lente 11 45 7.1 0.13 1885
8 5 M 7.1 DSH DM Insulin: glargine 18 24 5.7 0.09 .2000
9 10 M 6.0 DSH DM Insulin: lente 11 9 7.0 0.14 .2000
10 6 M 5.0 DLH DM Insulin: glargine 3 5 7.8 0.27 1391
11 15 M 5.0 DSH DM Insulin: glargine 4 5 7.0 0.12 1536
12 14 M 5.4 DSH DM, chronic enteropathy Insulin: glargine 1.5 0 5.8 0.06 1342
13 11 M 5.2 DSH DM Insulin: glargine 0 5.5 0.09 .2000
14 6 M 7.2 DSH DM Insulin: lente 0 4.5 0.07 1289
15 14 M 4.5 Maine Coon DM Insulin: PZI 19 4 6.6 0.08 1847
16 9 M 4.1 DSH DM Insulin: lente 5.5 6 6.1 0.09 1322
17 14 M 3.5 DSH DM, CKD Insulin: lente 7.5 2 0.0 N/A 1395
18 12 M 5.9 Maine Coon DM Insulin: lente 6 4 5.8 0.11 1672
19 10 M 5.6 DSH DM Insulin: lente 14 3 9 N/A 1500
20 6 M 3.5 DSH DM Insulin: glargine 1 1 5.4 0.07 1287
21 9 M 5.8 DSH DM Insulin: lente 2 3 5.5 N/A .2000
22 8 M 4.3 Maine Coon DM Insulin: lente,
PAS-SAR
21 5 11.1 0.65 .2000
23 11 F 5.5 DSH DM, chronic enteropathy Insulin: glargine,
PAS-LAR
15 19 8.5 0.40 .2000
24 8 M 4.6 DSH DM Insulin: lente 18 7 11.0 0.61 .2000
25 14 M 5.4 DSH DM, chronic enteropathy Insulin: lente 0 5 5.0 0.06 1382
26 10 M 5.4 DSH DM Insulin: glargine 3.5 3 5.0 0.05 1567
27 15 M 11.3 DSH DM Insulin: lente 0 21 10.0 N/A 1770
28 15 M 4.0 BSH DM Insulin: lente 0 8 5.2 0.03 .2000
29 13 M 5.7 DSH DM, CKD Insulin: glargine,
PAS-LAR
3 21 5.6 0.08 .2000
30 13 F 7.7 DSH DM Insulin: lente 4 5 6.3 N/A 1304
31 11 F 5.7 DSH DM Insulin: glargine 9 4 7.4 0.17 919
32 7 F 8.0 DLH DM Insulin: lente 7 4 6.2 0.12 1875
33 10 M 5.9 Bengal DM Insulin: lente 5 3 4.8 0.08 1188
(Continued)
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guidelines. Primary antibody incubation used anti-porcine GH at 1:6000 dilution, anti-
porcine PRL at 1:4000 dilution, and anti-SSTR2 [25] at 1:1600 dilution. Secondary antibody
incubation was performed using species-specific biotinylated antibodies (Vector Laboratories,
Peterborough, United Kingdom) for 30 minutes at RT followed by incubation with avidin/biotin
complex (Vector Laboratories) for 30 minutes at RT. Slides were then incubated with dia-
minobenzidine (DAB) chromogen (Vector Laboratories) for 2 minutes, followed by counter-
staining usingGills hematoxylin for 40 seconds at RT. Between each step the slideswerewashed
in PBS and 0.05% Tween® 20 for 5 minutes three times. Tissues were dehydrated in increasing
concentrations of ethanol and then slideswere coverslipped usingVectashield antifademounting
medium (Vector Laboratories) and analyzed. Negative control samples underwent immuno-
histochemistry as described above but without addition of the primary antibody, and positive
control samples were sections from a healthy mouse pituitary for GH and PRL, and from a
healthy human pituitary for SSTR2 immunostaining.
Representative immunostaining for GH and PRL are presented in Fig. 1. The percentage DAB
immunoreactivity of each tissue section was determined by obtaining high-resolution photomi-
crographs at magnification 3100 (Leica DM4000 B; Leica Microsystems, Milton Keynes, United
Kingdom) and stitching images from each tissue together using image editing software (Microsoft
Image Composite Editor 2.0 for Windows; Microsoft, Redmond, WA) to create a digital copy of the
tissue. Area measurements were performed using Volocity version 6.3.0 (PerkinElmer, Waltham,
MA). The area ofDAB labelingwasdetected by thresholding of hue and saturation.Any contiguous
object,5 pixels was considered noise and excluded before the total area of the detected object was
calculated. The total tissue areawas also detected and used to calculate percentageDABpositivity
of each tissue. Scoring of sections that used anti-SSTR2 antibodies as the primary antibody was
also performed by three individuals in a blinded manner using a semiquantitative scale as
previously described [26]. Immunoreactivity intensity was graded 0 to 3 (0, absent; 1, cytoplasmic
staining; 2, membranous staining in ,50% cells or incomplete membranous staining; and 3,
circumferential membranous staining in .5% cells; see Fig. 2 for examples). When there was a
conflict of the pituitary score between one reviewer but two agreed then the agreed-upon score was
used, and when all three reviewers disagreed then the average score was used.
E. Pituitary RNA Extraction, Analysis, and Selection of Reference Genes
Pituitary RNA was extracted from 10 cats without pituitary disease using the phenol
chloroform technique. The RNA pellet was resuspended in RNase-free water and underwent
on-column DNase treatment using a commercially available kit and following the manu-
facturer’s instructions (RNeasy Maxi kit; Qiagen, Manchester, United Kingdom). RNA
quantity and integrity were assessed using theNanodrop™ 1000 spectrophotometer (Thermo
Table 1. Clinical Data of Cats in the Control and Acromegalic Groups (Continued)
Age (y) Sex
Body
Weight
(kg) Breed Concurrent Disease Treatment
Insulin
(U/12 h)
Time
Diabetic
(m)
Pituitary
DV Height
(mm)
Pituitary
Volume
(cm3)
IGF1
(ng/mL)
34 9 F 6.6 BSH DM, chronic enteropathy Insulin: lente,
SAMe
5 5 7.2 0.17 1775
35 12 M 6.7 DSH DM Insulin: lente 11 N/R 7.0 0.08 .2000
36 9 M 4.4 DSH DM Insulin: lente 14 6 6.8 0.16 .2000
37 14 F 4.8 DSH DM Insulin: PZI, PAS-
LAR
0.5 13 6.0 N/A 1938
38 13 F 3.5 DSH DM, hypertrophic
cardiomyopathy
Insulin: lente 4 4 5.2 0.06 .2000
39 11 F 3.5 BSH DM Insulin: PZI 9 24 5.4 N/A 1210
All cats enrolled in this study were neutered.
Abbreviations: ASH, American shorthair; BSH, British shorthair; CKD, chronic kidney disease; DLH, domestic
longhair; DM, diabetes mellitus; DSH, domestic shorthair; F, female; HCM, hypertrophic cardiomyopathy; IMHA,
immune-mediated hemolytic anemia; M, male; N/A, not applicable; N/R, not recorded; PAS-LAR, pasireotide long-
acting release; PAS-SAR, pasireotide short-acting release; PZI, protamine zinc insulin; SAMe, S-adenosyl-l-
methionine.
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Fisher Scientific, Hemel Hempstead, United Kingdom) and Agilent 2100 Bioanalyzer
(Agilent Biotechnologies, Craven Arms, United Kingdom).
An aliquot of 100 ng of total pituitary RNAwas used to synthesize first-strand cDNA using
1 mL of oligo(dT) primer (Promega, Madison, WI) and ImProm-IITM reverse transcription
Figure 1. Representative photomicrographs of GH (A–C) and PRL (D–F) immunostaining.
(A and D) Immunoreactivity is identified by diaminobenzidine (DAB) chromogen and tissue
counterstaining performed using Gill hematoxylin. Photomicrographs demonstrating specific
immunostaining for somatrophs and lactotrophs, respectively. Original magnification, 340
(B and E). Photomicrographs of B–C and E–F were created by obtaining high-resolution
photomicrographs at magnification 3100 and stitching images from each tissue together
using image editing software. (B and E) Photomicrographs from a control cat. (C and F)
Photomicrographs from an acromegalic cat.
186 | Journal of the Endocrine Society | doi: 10.1210/js.2018-00226
D
ow
nloaded from
 https://academ
ic.oup.com
/jes/article-abstract/3/1/181/5128914 by guest on 03 M
arch 2020
system (Promega) per the manufacturer’s instructions with added magnesium chloride
(50 mM MgCl2; Bioline London, United Kingdom). The cDNA was eluted using 100 mL of
RNase-free water and stored at220°C until batch use. A nonreverse-transcribed sample was
prepared as a control for each sample. The selection of the reference genes for GeXPmultiplex
was performed using the geNorm algorithm [27] and feline geNorm 6 gene kit for use with
SYBR Green (PrimerDesign, Southampton, United Kingdom). An m value of ,0.5 was the
cutoff for selection. RPL18 and SDHA were chosen as the reference genes.
F. Multiplex RT-qPCR
Three custom-designed GeXP multiplexes (GenomeLab gene expression profiler; Beckman
Coulter, Wycombe, United Kingdom) were used to quantify gene expression. Multiplex 1
consisted of primers designed for AIP, CGA, FSHb, GHRHR, LHb, PRL, POU1F1, TSHb,
RPL18, and SDHA, multiplex 2 consisted of primers designed for POMC, GH1, RPL18, and
SDHA, and multiplex 3 consisted of primers for SSTR1, SSTR2, SSTR3, SSTR4, SSTR5,
DRD2, RPL18, and SDHA [28]. There were two primer sets for the measurement of PRL,
labeled as PRLa and PRLb, to investigate the precision of gene amplification using the GeXP
technique. The GeXP multiplex was performed as previously described and in accordance
with the manufacturer’s instructions [29, 30]. This procedure uses the GeXP start-up kit
(Beckman Coulter) to synthesize cDNA using gene-specific antisense primers with a 30
universal tag reverse sequence and 100 ng of total pituitary RNA using a G-Storm GS1
Figure 2. Representative images of SSTR2 immunoreactivity using feline pituitary tissue.
(A–D) Immunoreactivity is identified by diaminobenzidine (DAB) chromogen and tissue
counterstaining performed using Gill hematoxylin. Pituitary tissue exhibiting SSTR2
immunohistochemistry scores 0, 1, 2 and 3, respectively, using the following criteria: 0, absent; 1,
cytoplasmic staining; 2, membranous staining in ,50% cells or incomplete membranous staining;
and 3, circumferential membranous staining in .50% cells. All presented photomicrographs were
collected at an original magnification of 3100.
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thermal cycler and the following protocol: 48°C, 1 minute; 42°C, 60 minutes; and 95°C,
5 minutes. Following first-strand cDNA synthesis, an aliquot from each reaction was added
to a PCR master mix containing GenomeLab kit PCR master mix and DNA polymerase
(Thermo-Start DNApolymerase; Thermo Fisher Scientific, Loughborough, United Kingdom).
PCR reaction was performed using G-Storm GS1 thermal cycler and the following protocol:
95°C for 10 minutes, followed by 35 cycles at 94°C for 30 seconds, 55°C for 30 seconds for
multiplex 1 and 3 and 65°C for multiplex 2, and 70°C for 60 seconds. Products were analyzed
by separation using capillary electrophoresis followed by fluorescence spectrophotometry and
quantified using CEQTM 8000 genetic analysis system and GenomeLab fragment analysis
software (Beckman Coulter). Examples of electropherograms for multiplex 1 and 3 are
presented in Fig. 3. Because many samples had SDHA and POMC expression below the level
of detection, RPL18 was used as the sole reference gene and the difference between groups of
POMC expression was not undertaken.
G. Statistical Analysis
Data were visually assessed for normal distribution using histograms and by performing
Shapiro–Wilk tests. Normally distributed data are described as mean and SD and non-
normally distributed data as median and interquartile range (IQR). Statistical significance
was determined using an unpaired t test and Mann–Whitney test. A Spearman rank cor-
relation or Pearson correlation was used to test the association between gene expression and
clinical variables. Agreement of SSTR2 scores between observers was assessed using a two-
way random effects single measures intraclass correlation coefficient for absolute agreement
model. A x2 test was used to test the SSTR2 scores between acromegalic and control groups. A
P value of,0.05 was considered significant, and a Holm-Bonferroni adjustment was used for
adjustment of multiple comparisons where appropriate. Statistical software analyses were
Figure 3. Electropherogram results from PCR products using multiplex 1 primer sets. The
blue peaks represent PCR products from gene-specific primers and the red peaks represent
product size standards.
188 | Journal of the Endocrine Society | doi: 10.1210/js.2018-00226
D
ow
nloaded from
 https://academ
ic.oup.com
/jes/article-abstract/3/1/181/5128914 by guest on 03 M
arch 2020
performed using GraphPad Prism version 7.02 for Windows (GraphPad Software, La Jolla,
CA) and IBM SPSS Statistics for Windows version 22 (IBM Corporation, New York, NY).
2. Results
A. Reticulin Staining
The reticulin staining in the control pituitary glands demonstrated an acinar and cords
pattern (Fig. 4). This pattern is the same as described in the healthy human pituitary gland
[31]. The upper reference interval for the number of nuclei per acinus in the control pituitary
samples was 66, and the upper reference interval for the area of each acinus was 12,650 mm2.
The two remaining control pituitary samples were assessed using this scoring system and
both were considered within normal limits. A spectrum of altered reticulin staining was
identified in the HST pituitary samples, including enlargement of acini, disrupted reticulin
staining, and loss of reticulin staining (Fig. 5). Compression of the normal pituitary pa-
renchyma adjacent to neoplastic tissue was also identified that created a ring of cords of
Figure 4. Images stained using silver stain for reticulin fibers and counterstained using
nuclear fast red solution. (A and C) Reconstructed stitched pituitary photomicrographs from
two control pituitaries. Original magnification, 3100. (B and D) Enlarged photomicrographs
from sections of (A) and (C), respectively. Original magnification, 3400. The acinar pattern of
reticulin staining is identified in (B) and (D). This pattern of reticulin staining was
demonstrated in all reticulin staining control pituitaries.
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reticulin staining in some tissue samples. Three assessors reported 7 of 21 pituitaries
exhibited loss of acinus structure, which was described as diffuse or multifocal in all cases. Of
the remaining pituitaries, two assessors (Dr. Christopher Scudder and Katarina Hazuchova
for all 8 cases) described a loss of acinus structure in 8 of 14 cases, which was focal in 4 of 8
cases and multifocal or diffuse in the remaining 4 cases. All three assessors described an
increased in size of acini in 5of 21 pituitaries. Of the remaining pituitaries, two assessors
(Katarina Hazuchova and Norelene Harrington for all 5 pituitaries) described 5 of 16
pituitaries as having enlarged acini. There were no distinguishing clinical features of the 10
cats who were described to exhibit pituitary acinar enlargement (acromegaly cat nos. 7, 14,
22, 24, 25, 32, 34, 35, 36, and 38).
B. GH and PRL Expression
There was no difference of patient sex (x2 test, P = 0.334) or patient age (median control vs
HST was 11 vs 11 years, Mann–Whitney U test, P = 0.870) between groups, but there was a
Figure 5. All images stained using silver stain for reticulin fibers and counterstained using
nuclear fast red solution. (A–D) Selected images taken from reconstructed stitched pituitary
photomicrographs from four HST pituitaries. Original magnification, 3100. (A) Disrupted
reticulin staining and loss of acinar structure. (B) Areas of enlarged acini (blue stars) and
areas of loss of acinar structure (blue cross). (C) Enlarged acini (blue stars) adjacent to
normal size and small acini. (D) Loss of acinar structure in the bottom right of the image
(blue star); adenomatous tissue has compressed the normal pituitary tissue, resulting in
compression of the acini and a ring of cords of acini giving the impression of a pseudocapsule.
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difference in bodyweight (median control vs HSTwas 4.3 vs 5.4kg,Mann–WhitneyU test,P =
0.006). The difference in body weight between groups was expected and likely due to the
acromegalic state.
There was significantly greater GH protein expression in the HST compared with control
group (mean, 50% 6 27% vs 30% 6 21%; t(51) = 2.914, P = 0.005; Table 2). Although gene
expression of GH1 was greater in cats with acromegaly than in controls, this was not sta-
tistically significant (median control vs HSTwas 3.1 vs 6.2; Mann–WhitneyU test,P = 0.071).
There was no difference of PRL protein or gene expression between the HST and control
group [median protein expression, 1.5% (IQR, 10.9) vs 4.1% (IQR, 4.2); Mann–WhitneyU test,
P = 0.122; median relative gene expression, 2.099 (IQR, 1.7) vs 2.196 (IQR, 0.73); Mann–
Whitney U test, P = 0.033]. There was no correlation between patient age and GH or PRL
expression, nor was there an association between age and any pituitary gene expression in
this study.
C. SSTR2 Expression
There was no difference of patient sex (x2 test, P = 0.150), age (mean controls vs HST, 10.56
5.9 vs 11 6 3; t(34) = 0.392, P = 0.687) but there was a difference in body weight between
groups (median control vs HST was 4.1 vs 5.5 kg; P = 0.004).
There was agreement between observers for tissue SSTR2 scores (intraclass correlation,
0.57; 95% CI, 0.34 to 0.73; P , 0.001). Because of the low number of tissues having scores of
0 and 3, groups 0 to 1 and 2 to 3 were grouped together. There was no difference of proportions
of SSTR2 scores between acromegalic and control groups. The tissue percentage DAB pos-
itivity results are shown in Table 2. The percentage DAB-positive tissue for SSTR2 im-
munoreactivity was greater in the HST group than in controls (0.20% vs 0.016%; P = 0.026).
Nine samples had both SSTR2 expression data and SSTR2 immunohistochemistry data. A
positive correlation betweenSSTR2 gene expression and percentage tissueDAB stainingwas
detected (r2 = 0.76, P , 0.001).
D. Expression of Remaining Anterior Pituitary Hormone and Regulatory Receptor Genes
Five cats with HST had previously received pasireotide treatment. There was no difference of
any gene expression data in pasireotide-treated and untreated cats; therefore, pasireotide-
treated patients were not excluded. There were no differences between sex or ages of patients
between groups for expression data ofCGA,GH1,FSHb,PRL,TSHb,DRD2,SSTR1,SSTR2,
and SSTR5.
Expression of FSHb, PRL, and TSHb was detected in all pituitaries (Table 2). Expression
ofCGAwas not detected in one control pituitary, and LHb expression was not detected in one
control and four HST pituitaries. There were no significant differences of hormone expression
between control and HST pituitaries. In the HST group, there were strong correlations of
gene expression between the following hormones after adjustment of the P value for multiple
testing: CGA and FSHb, CGA and TSHb, and FSHb and TSHb; there was moderate cor-
relation between PRL and TSHb (Table 3).
The results of the expression of the SSTR1, SSTR2, SSTR5, and DRD2 for individuals
with HST are shown in Fig. 6. The expression of SSTR3 or SSTR4 was not detected. All
remaining receptors were detected in 14 of 19 of the HST group, with SSTR5 and DRD2
detected in all of the HST group. There was significantly greater expression of SSTR1,
SSTR2, and SSTR5 in theHST group compared with controls [0.093 vs 0.008,Mann–Whitney
U test, P = 0.007; 0.036 vs 0.002, t(25) = 23.34, P , 0.001; 0.151 vs 0.034, Mann–Whitney U
test, P = 0.004] (Fig. 3A). There was highly variable interpatient and intrapatient expression
of SSTR1, SSTR2, and SSTR5 mRNA in control and HST cats; there was moderate cor-
relation between SSTR1 and SSTR5 expression in the HST group (Spearman rho, 0.65; P =
0.005); in the control group this correlationwas not statically significant (Spearman rho, 0.71;
P = 0.18). No other receptor expression was correlated with one another. There was a
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Table 2. Gene Expression Data and GH, PRL, and SSTR2 Immunohistochemistry Scoring of Cats in the
Control and Acromegalic Groups
Relative Gene Expression
CGA FSHB GH1 LHB PRL TSHB SSTR1 SSTR2 SSTR5 DRD2
Control group
1 4.235 4.868 3.252 0.175 2.324 3.114 0 0 0.0123 0.643
2 5.500 8.317 3.666 0.307 1.502 2.709 0.01 0 0.0606 1.3891
3 16.915 1.553 1.178 1.436 1.886 0.01 0 0.0321 1.3724
4 2.341 2.536 0.080 1.399 0.844
5 5.802 4.775 1.173 0.546 2.918 2.524
6 4.453 4.742 0.506 2.099 0.952 0.03 0 0.0218 1.3121
7 17.060 20.215 7.620 13.866 0.01 0.0027 0.0224 1.0812
8 5.708 5.612 3.111 0.226 3.405 3.550 0 0 0 1.1168
9 2.937 2.857 1.673 0.443 1.965 2.223 0 0 0.0223 1.6752
10 3.279
11 5.127 0 0.0132 0.0653 0.9713
12 0.01 0.0063 0.0674 0.9928
13
14
15
16
17
18
19
20
21
22
HST group
1 1.604 2.116 0.031 1.598 0.562 0.11 0.0651 0.2217 0.7414
2 1.612 1.585 3.713 0.050 1.840 1.105 0.11 0.0223 0.3064 0.8585
3 1.500 0.574 0.147 0.646 0.097 0 0 0.0368 0.1674
4 2.527 2.585 1.978 2.035 0.25 0 0.2295 0.9474
5 6.742 7.484 6.750 1.256 1.202 0.03 0 0.0755 1.2558
6 4.522 5.488 0.325 2.588 2.432 0.01 0.0399 0.0888 1.6544
7 3.088 3.159 2.927 0.199 2.485 0.878 0.26 0.0631 0.3101 1.2568
8 6.023 6.820 0.096 1.865 3.042 0.03 0.0178 0.1172 0.5834
9 1.805 1.300 0.035 2.115 2.332 0.04 0 0.2361 0.7431
10 3.367 5.492 2.138 0.996 0.19 0.1519 0.1121 0.8297
11 4.138 4.230 1.893 0.237 2.537 2.151 0 0.0274 0.0545 2.5064
12 3.694 4.490 4.046 0.119 2.402 1.040 0.13 0.0716 0.1226 1.1431
13 37.371 45.779 11.229 26.894 0.09 0.0064 0.1566 0.7815
14 4.058 4.561 0.329 2.906 2.251
15 5.457 5.663 2.825 0.764 2.254 3.903 0.2 0.0331 0.0916 0.9225
16 5.550 5.751 0.252 3.401 2.319 0.02 0.0576 0.1575 1.0134
17 7.507 0.01 0.0204 0.0965 1.1995
18 27.799
19 3.442
20 6.247
21 15.611
22 0.938
23 6.802
24 15.611
25 2.207
26
27
28
29
30
31
32
33
34
35
36
37
38
39
(Continued)
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Table 2. Gene Expression Data and GH, PRL, and SSTR2 Immunohistochemistry Scoring of Cats in the
Control and Acromegalic Groups (Continued)
Relative Gene Expression IHC % DAB+
IHC % DAB+:
SSTR2 Reticulin StainingAIP GHRHR GHSR ESR1 ESR2 GPER1 GH PRL
0.3728 0.1996 0.0603 0.2047 0.4541 0.6316
0.4833 0.236 0.1165 0.4354 0.504 2.2935
2.7279 0.2031 0.0886 0.1574 0.5736 0.5146
0.2895 0.3056 0 0.0621 0.3556 0.4907 1.704 3.728 0.346
0 0 0 0.2755 0.8168 1.9429
0.2923 0.322 0.2332 0.2005 0.7558 1.6494 75.246 4.036 0.000 x
0.3575 0.2141 0.1753 0.3414 0.9114 0.5207 62.875 4.194 0.864 x
0.5914 0 0 0 0.0964 0.5344 29.303 6.927 0.013
0 0 0.2845 0 0.21 0.6574 45.826 1.557 0.057 x
0.525 4.168
0.296 0.3148 0.2885 0 0.3502 0 7.613 8.105 x
0.2788 0.2802 0.286 0 0.4769 0.3031 10.796 0.590 0.001 x
42.158 17.888 x
30.946 2.522 0.020 x
31.253 1.994 0.097
39.220 0.000
40.529 12.876 0.003 x
16.014 12.111 x
15.324 0.066 0.003 x
50.075 12.475 0.000 x
41.906 18.296 7.919 x
7.965 0.155 0.020
0.4326 0.2955 0.12 0.1245 0.2187 0.3345
0.3928 0.4603 0.1759 0.0559 0.4643 0.6155 95.615 1.256 1.269 x
0.4958 0.057 0.0201 0.1177 0.9463 1.4239
0.3919 0.2925 0.2299 0.1867 0.6055 0.5994 94.662 0.071 0.020
0.6529 0.3755 0.2365 0.3491 0.8696 0.6269 88.505 0.000 0.008
0.3397 0.2428 0.114 0 0.5608 1.1691
0.2912 0.4277 0.3374 0 0.354 0.7307 63.758 1.060 2.918 x
0.3269 0.2541 0.0757 0.1854 0.3736 0.3201 59.965 0.219
999 999 0.227 0.0101 0.2126 0.5632 55.064 7.518 0.579 x
0.5192 0.4121 0.2895 0.0301 0.474 0.6729 22.791 5.012 21.549 x
0.3744 0.1422 0.0206 0.0426 0.3217 0.3696 12.869 20.613 1.091 x
0.2437 0.3611 0.0867 0.3095 0.6685 0.2753 31.142 0.688 0.300
0.3222 0.3158 0.2002 0.162 0.5108 0.8293 9.999 0.521
1.2654 0.2225 0 0.2448 0.8086 1.2097 39.605 1.661 x
0.3447 0.3162 0.1094 8.009 0.471
0.3192 0.3566 0.1307 0.4555 1.0182 0.7893
0 0 0.1035 0 0.5831 0.5592 23.469 0.039 0.018
83.557 1.992 0.096 x
48.228 1.008 0.022
56.438 0.857 0.166
86.845 2.619 0.007
56.492 6.212 0.342 x
59.583 3.422
91.761 0.009 x
32.149 2.877 7.421 x
40.870 10.524 0.184
9.727 8.765 0.167 x
40.353 0.579 0.094 x
34.545 0.359 0.109 x
67.555 0.242 x
94.014 0.000 0.043 x
51.611 1.128 4.888 x
69.541 16.261 x
55.946 3.075 x
82.171 4.575 0.008 x
56.666 0.305 0.016 x
15.673 10.449
26.292 4.439 x
47.771 4.571
Abbreviation: IHC, immunohistochemistry.
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moderate negative correlation between DRD2 expression and pituitary volume within the
HST group (Spearman rho,20.52;P = 0.041). There was no association between somatostatin
receptor expression and IGF1 reduction due to pasireotide treatment in the cats that had
received pasireotide prior to pituitary tissue collection. There was also no association be-
tween somatostatin receptor expression and insulin dose or length of time receiving exog-
enous insulin therapy.
3. Discussion
Human and feline acromegaly share many clinical commonalities, and the disease appears to
be increasing in prevalence in both populations. Thismight in part be due to increased clinical
awareness and improved diagnostic tests. This study describes reticulin staining patterns as
well as hormone and regulatory receptor expression in the normal and acromegalic feline
pituitary for the first time. A description of the normal feline pituitary gland was required
because of the paucity of currently available information.
The percentage of GH- and PRL-positive cells in the normal cat pituitary was lower than
reported in adult humans (28% vs 45% and 4% vs 15% to 25%, respectively) [32, 33]. As the
predominant cell type of acidophils are GH-secreting cells, the distribution of acidophils
within a hematoxylin and eosin–stained anterior pituitary section largely reflects the dis-
tribution of the GH-producing cells within the feline pituitary gland in health.
There was no consistent pattern of distribution of GH-producing cells in the normal feline
pituitary. These cells were seen to cluster or be evenly distributed throughout the anterior
pituitary. This pattern differs from the human pituitary where somatotrophs are pre-
dominantly located within the lateral wings [33]. PRL-producing cells tended to form clusters
of up to 20 cells. This pattern differs from the distribution in humans where they typically
occur singularly. However, in concordance with humans, there was no specific location within
the gland where the PRL-producing cells were seen [32]
Mixed GH and PRL adenomas or mammosomatotroph adenomas account for up to 30% of
cases of acromegaly in humans [34, 35]. PRL-positive cells accounted for ,10% of positive
cells in 87% of the acromegalic pituitaries, with the remaining samples containing 10.5%,
10.5%, 16%, and 20.5% of PRL-positive cells. Therefore, mixed GH and PRL adenomas/
mammosomatotroph adenomas were not a predominant feature of acromegaly in these cats.
The prevalence of pituitary hyperplasia was greater than anticipated. It has been proposed
that hyperplastic change can precede adenomatous transformation in human patients, and
somatotroph hyperplasia has been shown to result in somatotroph adenoma formation in
GHRH-overexpressing mice [10, 36, 37]. Somatotroph hyperplasia is considered a rare cause
of acromegaly in humans [38]. The prevalence of pituitary hyperplasia might be greater than
suggested by these results if the progression from hyperplasia to adenoma occurs in cats and
Table 3. Summary of Spearman Rank Correlation Gene Expression Data in the Control Group and
Acromegalic Groups
Group Gene Correlate to Gene Spearman Rho P Value Adjusted P Value
Control PRL Versus TSHb 0.800 0.010 0.104
CGA Versus PRL 0.810 0.015 0.104
CGA Versus FSHb 0.786 0.021 0.104
CGA Versus TSHb 0.714 0.047 0.150
Acro CGA Versus FSHb 0.979 , 0.001 0.005
CGA Versus TSHb 0.937 , 0.001 0.005
FSHb Versus TSHb 0.930 , 0.001 0.005
CGA Versus PRL 0.615 0.033 0.092
FSHb Versus PRL 0.615 0.033 0.092
Abbreviation: Acro, acromegalic.
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the hyperplasia stage is missed because many cats are not diagnosed until the onset of
diabetes mellitus.
Cats expressed SSTR1, SSTR2, and SSTR5 whereas SSTR3 and SSTR4 proved un-
detectable using the employed methodology. Expression of DRD2 was identified in all feline
pituitaries. Cats displayed a similar pituitary SSTR andDRD2 profile to humans. These data
provide therapeutic targets for the management of acromegaly in cats and substantiates the
comparative potential of studying the acromegalic cat as a spontaneously occurring model of
the human disease [12].
Previous reports of SSTR mRNA expression in GH-secreting pituitary adenomas in
humans describe SSTR5 . SSTR2 whereas SSTR1 and SSTR3 expression can be highly
variable and SSTR4 expression is absent [39–43]. Immunohistochemical reports describe
somatotroph receptor expression as either SSTR2 . SSTR5 or SSTR5 . SSTR2 [44–46].
However, these conflicting reports might have occurred owing to a difference in proportion of
sparsely vs densely granulated adenomas in the studied groups. These tumor subtypes,
Figure 6. (A) Bar charts comparing the relative gene expression of SSTR1, SSTR2, and
SSTR5 in pituitary tissue from control (CTRL) and acromegalic (Acro) cats determined using
the GeXP multiplex technique. RPL18 is the reference gene. Bar height represents mean,
and error bars are 95% CIs. **P , 0.01, ***P , 0.001. (B) Dot plot of the individual
somatostatin profiles from each of the 19 acromegalic cats.
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which can be differentiated by electromicroscopy or CAM5.2 immunoreactivity pattern, have
been documented to have different somatostatin receptor expression profiles [44, 47, 48].
Protein expression of SSTR2 in cats as assessed by immunohistochemistry scoring was lower
than that reported in humans [44, 48]. This may be a reason for the previously under-
whelming response to octreotide in acromegalic cats, because SSTR2 expression has been
positively correlated with octreotide response in humans [18, 42, 49]. Only one cat in the
acromegalic group exhibited diffuse strong SSTR2 expression, which suggests that certain
individual cats might be suitable candidates to receive octreotide to manage their acro-
megaly. The lower SSTR2 expression identified in the cats in this study might be because we
did not differentiate between sparsely or densely granulated tumors. Finally, the detected
positive correlation between SSTR2 gene expression as measured by GeXP multiplex and
protein levels as measured through immunohistochemistry parallels findings from previous
studies, further supporting the robustness of this methodology for within-gene expression
assessment [48, 50].
There are several different somatostatin receptor immunostaining scoring systems where
immunoreactivity is categorized using semiquantitative systems dependent on pathologist
description of staining [26, 47, 51] or percentage cells with staining [44]. The current study
employed semiquantitative analyses that assessed subcellular location of staining and
quantification by percentage of DAB-positive tissue. The results of the semiquantitative
analyses revealed that the interobserver agreement was only fair. Therefore, the percentage
DAB-positive tissue was used to analyze SSTR2 immunoreactivity instead. This type of
analysis is only as reliable as the defined color spectrum cutoff for the presence or absence of
staining. The program for this analysis was designed to be highly specific for positively
stained tissue. This might have lowered the sensitivity for the identification of weakly
positively stained tissue and favored identification of the strongmembranous staining, which
was typicallymore darkly stained than cytoplasmic staining. However, the latter could in fact
be more appropriate because membranous staining is more heavily weighted when scored
in many of the semiquantitative scoring systems; additional reassurance was provided by
the fact that immunohistochemical analysis data exhibited strong correlation with gene
expression data.
The entire acromegalic group expressed DRD2 whereas DRD2 expression is not found so
consistently in human samples [46, 52, 53]; PRL expression was also detected in all samples.
Therefore, the presence of DRD2 might have been due to the presence of lactotrophs. In
veterinary medicine, acromegalic cats undergo therapeutic total hypophysectomy rather
than adenomectomy surgery, whichmight result in healthy pituitary tissue being adherent to
the adenoma. Nevertheless, there was no correlation between PRL expression and DRD2
expression, which argues against this and would be consistent with tumorous somatotroph
DRD2 expression.
There was no difference in DRD2 expression between acromegalic and control cats,
although a moderate negative correlation between DRD2 expression and pituitary size was
detected. Dopamine has been shown to block cell cycle progression, and activation ofDRD2 by
dopamine in a gastric cancer cell model has been shown to suppress cancer cell invasion [54,
55]. Additionally, the loss ofDRD2 in mice resulted in large prolactinomas [56].DRD2 loss in
the pituitary might therefore also promote large somatotroph tumor formation in cats. These
data also suggest that dopamine agonist therapy should be further evaluated in acromegalic
cats and particularly in those with smaller pituitary tumors, because resistance to dopamine
agonist therapy has been associated with lower DRD2 expression in human GH-secreting
adenomas [53].
One potential limitation to the study was that all cats with acromegaly were diabetic and
receiving exogenous insulin. Previous studies in fish have shown SSTR expression to increase
in a dose-dependent manner when exposed to increasing concentrations of insulin and
glucose in the acute setting [57, 58]; whether this effect is sustained for.24 hours has not yet
been reported. Our current studies found no correlations between SSTR expression and
insulin dose or length of time the cat had been receiving exogenous insulin. Therefore, these
196 | Journal of the Endocrine Society | doi: 10.1210/js.2018-00226
D
ow
nloaded from
 https://academ
ic.oup.com
/jes/article-abstract/3/1/181/5128914 by guest on 03 M
arch 2020
findings suggest that chronic hyperglycemia or insulin therapy might not affect pituitary
somatostatin receptor expression in cats.
In conclusion, the current study data reveal the heterogeneous expression of SSTRs in the
pituitary gland from domestic cats without pituitary disease and those with acromegaly.
Additionally, in parallel with human medicine, DRD2 expression was correlated with pi-
tuitary tumor size in acromegalic cats. This study has revealed several parallels between
humans and cats with acromegaly in terms of inhibitory receptor profiles. This receptor
characterization aids our understanding of the morphology of the feline pituitary, and data
suggest acromegalic cats as amodel of the human disease in terms of developing therapeutics
for GH inhibition.
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